2 unknown. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Nuron Biotech Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers NU300, ActHIB, Prevnar 13 - Infectious Disease | Phase 2 | Unknown | Nuron Biotech Inc. | 220 | 2013-03-01 | 2013-09-23 |
| Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) NU100, Placebo, rhIFN beta-1b - Relapsing Remitting Multiple Sclerosis | Phase 3 | Unknown | Nuron Biotech Inc. | 500 | 2011-10-01 | 2013-09-23 |
Communicable Diseases (1) · Multiple Sclerosis, Relapsing-Remitting (1)
13-valent pneumococcal vaccine (1) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (1)
Belarus (1) · Bulgaria (1) · Croatia (1) · Georgia (1) · Hungary (1) · Italy (1) · Lebanon (1) · Poland (1) · Russia (1) · Serbia (1) · Spain (1) · Ukraine (1) · United States (1)